Sanofi (NASDAQ:SNY) Rating Increased to Hold at Deutsche Bank Aktiengesellschaft

Sanofi (NASDAQ:SNY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a research note issued on Thursday,Briefing.com Automated Import reports.

Separately, StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $60.00.

Sanofi Stock Performance

SNY stock traded up $1.99 during midday trading on Thursday, reaching $54.14. 4,532,973 shares of the company were exchanged, compared to its average volume of 2,650,813. Sanofi has a one year low of $45.22 and a one year high of $58.97. The firm has a market capitalization of $137.41 billion, a price-to-earnings ratio of 27.62, a price-to-earnings-growth ratio of 1.19 and a beta of 0.57. The business has a 50-day moving average price of $48.99 and a two-hundred day moving average price of $52.22. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. Equities research analysts forecast that Sanofi will post 3.82 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Synergy Asset Management LLC acquired a new stake in Sanofi during the 4th quarter worth approximately $25,000. McClarren Financial Advisors Inc. grew its stake in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after purchasing an additional 543 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in Sanofi in the third quarter valued at $29,000. Concord Wealth Partners raised its position in Sanofi by 157.8% during the 3rd quarter. Concord Wealth Partners now owns 593 shares of the company’s stock worth $34,000 after purchasing an additional 363 shares during the last quarter. Finally, Fortitude Family Office LLC lifted its holdings in Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after buying an additional 659 shares during the period. Institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.